The estimated Net Worth of Gary P. Pisano is at least 504 千$ dollars as of 13 August 2021. Gary Pisano owns over 81,433 units of Axcella Health Inc stock worth over 372,963$ and over the last 8 years he sold AXLA stock worth over 0$. In addition, he makes 131,426$ as Independent Director at Axcella Health Inc.
Sign up
Gary Pisano AXLA stock SEC Form 4 insiders trading
Gary has made over 2 trades of the Axcella Health Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 81,433 units of AXLA stock worth 22,801$ on 13 August 2021.
The largest trade he's ever made was exercising 81,433 units of Axcella Health Inc stock on 13 August 2021 worth over 22,801$. On average, Gary trades about 6,667 units every 125 days since 2016. As of 13 August 2021 he still owns at least 81,433 units of Axcella Health Inc stock.
You can see the complete history of Gary Pisano stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gary Pisano biography
Dr. Gary P. Pisano serves as Independent Director of the Company. Dr. Pisano is the Harry E. Figgie, Jr. Professor of Business Administration and Senior Associate Dean for Faculty Development at the Harvard Business School. He has served on the Harvard faculty since 1988. Dr. Pisano's research and teaching focus on technology and operations strategy, the management of innovation and intellectual property, and competitive strategy. For more than two decades, he has consulted extensively on these issues with companies in the pharmaceutical, biotechnology, medical device, specialty chemical and healthcare industries. He has previously served as a director of Axovant Sciences Ltd. (Nasdaq: AXON) and Patheon NV (NYSE: PTHN).
What is the salary of Gary Pisano?
As the Independent Director of Axcella Health Inc, the total compensation of Gary Pisano at Axcella Health Inc is 131,426$. There are 8 executives at Axcella Health Inc getting paid more, with Shreeram Aradhye having the highest compensation of 3,911,720$.
How old is Gary Pisano?
Gary Pisano is 58, he's been the Independent Director of Axcella Health Inc since 2011. There are 2 older and 14 younger executives at Axcella Health Inc. The oldest executive at Axcella Health Inc is Catherine Sohn, 67, who is the Independent Director.
What's Gary Pisano's mailing address?
Gary's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Insiders trading at Axcella Health Inc
Over the last 6 years, insiders at Axcella Health Inc have traded over 32,393$ worth of Axcella Health Inc stock and bought 29,966,648 units worth 79,278,835$ . The most active insiders traders include Ventures Fund Iv General Pa...、Ventures Fund Iv General Pa...、Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of 3,073,698$. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth 394$.
What does Axcella Health Inc do?
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
What does Axcella Health Inc's logo look like?
Complete history of Gary Pisano stock trades at Axcella Health Inc
Axcella Health Inc executives and stock owners
Axcella Health Inc executives and other stock owners filed with the SEC include:
-
Shreeram Aradhye,
Executive Vice President, Chief Development Officer -
Manu Chakravarthy,
Senior Vice President, Chief Medical Officer -
William Hinshaw,
President, Chief Executive Officer, Director -
David Epstein,
Chairman of the Board -
William R. Hinshaw Jr.,
Pres, CEO & Director -
Laurent Chardonnet,
Consultant -
William Baird,
Independent Director -
Catherine Sohn,
Independent Director -
Gary Pisano,
Independent Director -
Gregory Behar,
Independent Director -
Cristina Rondinone,
Independent Director -
Stephen Hoge,
Independent Director -
Stephen Mitchener,
Senior Vice President, Chief Business Officer -
Paul Fehlner,
Senior Vice President, Chief Intellectual Property Officer -
Heidy King-Jones,
Senior Vice President of Legal, General Counsel -
Tony Tramontin,
Senior Vice President of Research and Development , Chief Scientific Officer -
Laurent Chardonnet,
Chief Financial Officer, Senior Vice President -
Karim Azer Ph.D.,
VP of Systems Biology & Discovery -
Dr. Margaret Koziel M.D.,
Sr. VP & Chief Medical Officer -
Dr. Alison D. Schecter M.D.,
Pres of R&D -
Dr. Larry Bell,
Global Head of Regulatory Affairs & Pharmacovigilance and Sr. VP -
Virginia R. Dean,
Sr. VP & Chief People Officer -
Dr. Paul Fehlner J.D., Ph.D.,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Jason Fredette,
VP of Investor Relations & Corp. Communications -
Health Science Us Holdings,...,
-
Michael Rosenblatt,
Director -
David A Berry,
Director -
Ventures Fund Iv General Pa...,
-
Paul J Sekhri,
Director -
Ventures Fund Iv General Pa...,
-
Des Produits Nestle S.A.Nes...,
-
Alison D. Schecter,
President - Research & Dev. -
Virginia R Dean,
SVP, Chief People Officer -
Margaret Koziel,
Chief Medical Officer -
Ventures Fund Iv General Pa...,
-
Robert Crane,
Chief Financial Officer -
Torben Straight Nissen,
Director -
Robert L. Rosiello,
Director